Emcure Pharmaceuticals IPO backed by Bain Capital- 3 July GMP issue size 1952.03cr
The Emcure Pharmaceuticals IPO is a substantial offering with an issue size of ₹1,952.03 crores. This includes a fresh issue of 0.79 crore shares amounting to ₹800.00 crores and an offer for sale of 1.14 crore shares aggregating to ₹1,152.03 crores.
The IPO opens for subscription on July 3, 2024, and will close on July 5, 2024. The allotment of shares is expected to be finalized by Monday, July 8, 2024. Investors can look forward to the listing of Emcure Pharmaceuticals on both the BSE and NSE, with the tentative listing date set for Wednesday, July 10, 2024
Emcure Pharmaceuticals IPO , a stalwart in the pharmaceutical sector, is making waves with its upcoming Initial Public Offering (IPO). Let’s delve into everything you need to know about this much-anticipated event.
Emcure Pharmaceuticals IPO Details
Emcure Pharmaceuticals is set to launch its IPO with a total issue size of ₹1,952.03 crores. This includes a fresh issue of 0.79 crore shares valued at ₹800.00 crores and an offer for sale of 1.14 crore shares amounting to ₹1,152.03 crores.
Key Dates and Price Band
The IPO opens for subscription on July 3, 2024, and closes on July 5, 2024. The price band is set between ₹960 to ₹1008 per share, with a minimum lot size of 14 shares, requiring a minimum investment of ₹14,112 for retail investors.
Emcure Pharmaceuticals IPO GMP and Valuation
The Grey Market Premium (GMP) for Emcure Pharmaceuticals IPO reflects investor sentiment and demand ahead of its listing. Reviews on the IPO’s valuation suggest it’s competitively priced, considering the company’s market position and growth prospects.
Ownership and Backing
Emcure Pharmaceuticals is backed by Bain Capital, highlighting strong investor confidence and strategic backing from a leading global investment firm.
Financial Performance and Profitability
Emcure Pharmaceuticals has demonstrated profitability, showcasing robust financial health amidst its growth trajectory. The company’s revenue growth and profitability metrics underscore its strong position in the pharmaceutical market.
Market Position and Cap
Ranked 13th in domestic sales among Indian pharmaceutical companies, Emcure Pharmaceuticals holds a significant market share, particularly in therapeutic areas like gynaecology and HIV antivirals. Its market cap reflects its standing and potential in the industry.
Emcure Pharmaceuticals IPO important dates related to Emcure Pharmaceuticals IPO
Emcure Pharmaceuticals IPO: Data Table and Important Dates
| Parameter | Details |
|---|---|
| IPO Date | July 3, 2024 to July 5, 2024 |
| Listing Date | To be announced |
| Face Value | ₹10 per share |
| Price Band | ₹960 to ₹1008 per share |
| Lot Size | 14 Shares |
| Total Issue Size | 19,365,346 shares (₹1,952.03 Cr) |
| Fresh Issue | 7,936,507 shares (₹800.00 Cr) |
| Offer for Sale | 11,428,839 shares (₹1,152.03 Cr) |
| Employee Discount | ₹90 per share |
| Issue Type | Book Built Issue IPO |
| Listing Platforms | BSE, NSE |
| Shareholding Pre Issue | 180,852,116 shares |
| Shareholding Post Issue | 188,788,623 shares |
| QIB Allocation | Not more than 50% of the Net Issue |
| Retail Allocation | Not less than 35% of the Net Issue |
| NII (HNI) Allocation | Not more than 15% of the Net Issue |
| Basis of Allotment Date | Monday, July 8, 2024 |
| Initiation of Refunds Date | Tuesday, July 9, 2024 |
| Credit of Shares to Demat Date | Tuesday, July 9, 2024 |
| Cut-off time for UPI Mandate | 5 PM on July 5, 2024 |
This table provides a concise overview of the key data points and important dates related to the Emcure Pharmaceuticals IPO, helping potential investors grasp the essential details at a glance.
Debt and Issue Size
Post-IPO, Emcure Pharmaceuticals plans to use proceeds to reduce its debt burden, which is seen as a positive step towards strengthening its balance sheet and enhancing profitability.
Conclusion: To Invest or Not?
Investors evaluating Emcure Pharmaceuticals IPO should consider its strong market presence, financial performance, and strategic backing. While the IPO is priced competitively, potential investors should conduct thorough due diligence or consult financial advisors to make informed decisions. Emcure Pharmaceuticals IPO presents a compelling opportunity in the pharmaceutical sector, backed by solid fundamentals and strategic initiatives.